{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T03:02:38Z","timestamp":1740106958347,"version":"3.37.3"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T00:00:00Z","timestamp":1722643200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Neurolixis"},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-11-IDEX-0007","ANR-11-IDEX-0007"],"award-info":[{"award-number":["ANR-11-IDEX-0007","ANR-11-IDEX-0007"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006687","name":"Universit\u00e9 Claude Bernard Lyon 1","doi-asserted-by":"publisher","award":["ANR-11-LABX-0063","ANR-11-LABX-0063"],"award-info":[{"award-number":["ANR-11-LABX-0063","ANR-11-LABX-0063"]}],"id":[{"id":"10.13039\/501100006687","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000864","name":"Michael J. Fox Foundation for Parkinson's Research","doi-asserted-by":"publisher","award":["Grant #9233","Grant #9233"],"award-info":[{"award-number":["Grant #9233","Grant #9233"]}],"id":[{"id":"10.13039\/100000864","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1007\/s00210-024-03323-0","type":"journal-article","created":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T09:02:05Z","timestamp":1722675725000},"page":"991-1002","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacodynamic, pharmacokinetic and rat brain receptor occupancy profile of NLX-112, a highly selective 5-HT1A receptor biased agonist"],"prefix":"10.1007","volume":"398","author":[{"given":"Ronan Y.","family":"Depoort\u00e8re","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Vidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Varney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luc","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adrian","family":"Newman-Tancredi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,8,3]]},"reference":[{"issue":"5","key":"3323_CR1","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/sj.npp.1300390","volume":"29","author":"RA Bantick","year":"2004","unstructured":"Bantick RA, Rabiner EA, Hirani E et al (2004) Occupancy of agonist drugs at the 5-HT1A receptor. Neuropsychopharmacology\u202f: Official Publication of the American College of Neuropsychopharmacology 29(5):847\u2013859","journal-title":"Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology"},{"issue":"3","key":"3323_CR2","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1124\/jpet.104.077669","volume":"312","author":"L Bardin","year":"2005","unstructured":"Bardin L, Assie MB, Pelissou M et al (2005) Dual, hyperalgesic, and analgesic effects of the high-efficacy 5-hydroxytryptamine 1A (5-HT1A) agonist F 13640 [(3-chloro-4-fluoro-phenyl)-[4-fluoro-4-{[(5-methyl-pyridin-2-ylmethyl)-amino]-me thyl}piperidin-1-yl]methanone, fumaric acid salt]: relationship with 5-HT1A receptor occupancy and kinetic parameters. J Pharmacol Exp Ther 312(3):1034\u20131042","journal-title":"J Pharmacol Exp Ther"},{"issue":"1","key":"3323_CR3","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1124\/pr.118.015552","volume":"73","author":"NM Barnes","year":"2021","unstructured":"Barnes NM, Ahern GP, Becamel C et al (2021) International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 73(1):310\u2013520","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3323_CR4","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.3390\/ijms22041927","volume":"22","author":"DO Borroto-Escuela","year":"2021","unstructured":"Borroto-Escuela DO, Ambrogini P, Chruscicka B et al (2021) The Role of Central Serotonin Neurons and 5-HT Heteroreceptor Complexes in the Pathophysiology of Depression: A Historical Perspective and Future Prospects. Int J Mol Sci 22(4):1927","journal-title":"Int J Mol Sci"},{"issue":"3","key":"3323_CR5","doi-asserted-by":"publisher","first-page":"147","DOI":"10.3109\/00498258309052248","volume":"13","author":"S Caccia","year":"1983","unstructured":"Caccia S, Muglia M, Mancinelli A et al (1983) Disposition and metabolism of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine in the rat. Xenobiotica 13(3):147\u2013153","journal-title":"Xenobiotica"},{"issue":"9","key":"3323_CR6","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","volume":"27","author":"P Celada","year":"2013","unstructured":"Celada P, Bortolozzi A, Artigas F (2013) Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: rationale and current status of research. CNS Drugs 27(9):703\u2013716","journal-title":"CNS Drugs"},{"key":"3323_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.nicl.2023.103497","volume":"39","author":"S Chaib","year":"2023","unstructured":"Chaib S, Vidal B, Bouillot C et al (2023) Multimodal imaging study of the 5-HT(1A) receptor biased agonist, NLX-112, in a model of L-DOPA-induced dyskinesia. Neuroimage Clin 39:103497","journal-title":"Neuroimage Clin"},{"issue":"1","key":"3323_CR8","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1007\/s00259-019-04473-7","volume":"47","author":"M Colom","year":"2020","unstructured":"Colom M, Costes N, Redoute J et al (2020) [18F]-F13640 PET imaging of functional receptors in humans. Eur J Nucl Med Mol Imaging 47(1):220\u2013221","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3323_CR9","doi-asserted-by":"publisher","first-page":"622423","DOI":"10.3389\/fnins.2021.622423","volume":"15","author":"M Colom","year":"2021","unstructured":"Colom M, Vidal B, Fieux S et al (2021) [(18)F]F13640, a 5-HT1A Receptor Radiopharmaceutical Sensitive to Brain Serotonin Fluctuations. Front Neurosci 15:622423","journal-title":"Front Neurosci"},{"issue":"6","key":"3323_CR10","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1007\/s00259-022-06103-1","volume":"50","author":"P Courault","year":"2023","unstructured":"Courault P, Lancelot S, Costes N et al (2023) [(18)F]F13640: a selective agonist PET radiopharmaceutical for imaging functional 5-HT(1A) receptors in humans. Eur J Nucl Med Mol Imaging 50(6):1651\u20131664","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"3323_CR11","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1038\/jcbfm.2009.190","volume":"30","author":"VJ Cunningham","year":"2010","unstructured":"Cunningham VJ, Rabiner EA, Slifstein M et al (2010) Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab 30(1):46\u201350","journal-title":"J Cereb Blood Flow Metab"},{"key":"3323_CR12","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.parkreldis.2020.08.009","volume":"78","author":"R Depoortere","year":"2020","unstructured":"Depoortere R, Johnston TH, Fox SH et al (2020) The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques. Parkinsonism Relat Disord 78:151\u2013157","journal-title":"Parkinsonism Relat Disord"},{"key":"3323_CR13","doi-asserted-by":"publisher","first-page":"107997","DOI":"10.1016\/j.neuropharm.2020.107997","volume":"167","author":"R Fisher","year":"2020","unstructured":"Fisher R, Hikima A, Morris R et al (2020) The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets. Neuropharmacology 167:107997","journal-title":"Neuropharmacology"},{"key":"3323_CR14","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","volume":"271","author":"H Iderberg","year":"2015","unstructured":"Iderberg H, McCreary AC, Varney MA et al (2015) NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat. Exp Neurol 271:335\u2013350","journal-title":"Exp Neurol"},{"issue":"7","key":"3323_CR15","doi-asserted-by":"publisher","first-page":"3108","DOI":"10.1021\/acschemneuro.8b00584","volume":"10","author":"E Levigoureux","year":"2019","unstructured":"Levigoureux E, Vidal B, Fieux S et al (2019) Serotonin 5-HT1A receptor biased agonists induce different cerebral metabolic responses: A [18F]FDG PET study in conscious and anesthetized rats. ACS Chem Neurosci 10(7):3108\u20133119","journal-title":"ACS Chem Neurosci"},{"issue":"9","key":"3323_CR16","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/jphp.12762","volume":"69","author":"A Newman-Tancredi","year":"2017","unstructured":"Newman-Tancredi A, Martel JC, Cosi C et al (2017) Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist. J Pharm Pharmacol 69(9):1178\u20131190","journal-title":"J Pharm Pharmacol"},{"key":"3323_CR17","doi-asserted-by":"publisher","first-page":"107937","DOI":"10.1016\/j.pharmthera.2021.107937","volume":"229","author":"A Newman-Tancredi","year":"2022","unstructured":"Newman-Tancredi A, Depoortere RY, Kleven MS et al (2022) Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders. Pharmacol Ther 229:107937","journal-title":"Pharmacol Ther"},{"key":"3323_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-017-1823-7","author":"G Pagano","year":"2017","unstructured":"Pagano G, Niccolini F, Politis M (2017) The serotonergic system in Parkinson\u2019s patients with dyskinesia: evidence from imaging studies. J Neural Transm (vienna). https:\/\/doi.org\/10.1007\/s00702-017-1823-7","journal-title":"J Neural Transm (vienna)"},{"key":"3323_CR19","unstructured":"Paillard B, Del Frari L, Brunner V, et al. (2016) A method for treating movement disorders with befiradol. In: WO2016\/005527A1 (ed)."},{"key":"3323_CR20","volume-title":"The Rat Brain in Stereotaxic Coordinates","author":"G Paxinos","year":"2007","unstructured":"Paxinos G, Watson C (2007) The Rat Brain in Stereotaxic Coordinates. Academic Press"},{"key":"3323_CR21","doi-asserted-by":"publisher","unstructured":"Pourhamzeh M, Moravej FG, Arabi M, et al (2021) The Roles of Serotonin in Neuropsychiatric Disorders. Cell Mol Neurobiol. Epub ahead of print 2021\/03\/03. https:\/\/doi.org\/10.1007\/s10571-021-01064-9","DOI":"10.1007\/s10571-021-01064-9"},{"issue":"2\u20133","key":"3323_CR22","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","volume":"453","author":"EP Prinssen","year":"2002","unstructured":"Prinssen EP, Colpaert FC, Koek W (2002) 5-HT1A receptor activation and anti-cataleptic effects: high-efficacy agonists maximally inhibit haloperidol-induced catalepsy. Eur J Pharmacol 453(2\u20133):217\u2013221","journal-title":"Eur J Pharmacol"},{"key":"3323_CR23","unstructured":"Svenningsson P, Odin P, Bergquist F, et al (2023) NLX-112 has favorable safety, tolerability and efficacy against levodopa-induced dyskinesia (LID) in a randomized, double-blind, placebo-controlled, proof-of-concept Ph2A study. In: World Parkinson\u2019s Congress, July 4\u20137, 2023, Barcelona, Poster Board #LBP38.31"},{"issue":"3","key":"3323_CR24","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1002\/syn.21721","volume":"68","author":"A Takano","year":"2014","unstructured":"Takano A, Gulyas B, Varnas K et al (2014) Low brain CB1 receptor occupancy by a second generation CB1 receptor antagonist TM38837 in comparison with rimonabant in nonhuman primates: a PET study. Synapse 68(3):89\u201397","journal-title":"Synapse"},{"issue":"Supp. 1","key":"3323_CR25","first-page":"1100","volume":"55","author":"B Vidal","year":"2014","unstructured":"Vidal B, Fieux S, Billard T et al (2014) Radiopharmacological evaluation of [18F]F13640, a novel 5-HT1A receptor agonist. J Nuclear Medicine 55(Supp. 1):1100","journal-title":"J Nuclear Medicine"},{"issue":"6","key":"3323_CR26","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s00429-018-1672-7","volume":"223","author":"B Vidal","year":"2018","unstructured":"Vidal B, Fieux S, Colom M et al (2018) [18F]-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging. Brain Struct Funct 223(6):2973\u20132988","journal-title":"Brain Struct Funct"},{"key":"3323_CR27","doi-asserted-by":"publisher","first-page":"107867","DOI":"10.1016\/j.neuropharm.2019.107867","volume":"172","author":"B Vidal","year":"2020","unstructured":"Vidal B, Bolbos R, Redoute J et al (2020) Pharmacological MRI to investigate the functional selectivity of 5-HT1A receptor biased agonists. Neuropharmacology 172:107867","journal-title":"Neuropharmacology"},{"issue":"3","key":"3323_CR28","doi-asserted-by":"publisher","first-page":"1257","DOI":"10.3233\/JPD-212580","volume":"11","author":"B Vidal","year":"2021","unstructured":"Vidal B, Levigoureux E, Chaib S et al (2021) Different alterations of agonist and antagonist binding to 5-HT1A receptor in a rat model of Parkinson\u2019s disease and levodopa-induced dyskinesia\u202f: a microPET study. Journal of Parkinson Disease 11(3):1257\u20131269","journal-title":"Journal of Parkinson Disease"}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-024-03323-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-024-03323-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T09:02:05Z","timestamp":1738400525000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-024-03323-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,3]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["3323"],"URL":"https:\/\/doi.org\/10.1007\/s00210-024-03323-0","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"type":"print","value":"0028-1298"},{"type":"electronic","value":"1432-1912"}],"subject":[],"published":{"date-parts":[[2024,8,3]]},"assertion":[{"value":"20 March 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ANT, MAV and RYD are shareholders and\/or employees of Neurolixis. The other authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}